Fierce Biotech Next Gen 2022 has ended

Create Your Own Event

Fierce Biotech Next Gen 2022

9:30am EDT

Alzheimer’s: What comes after Aduhelm?Annalee Armstrong • Brandy Matthews, M.D., FAAN • Gregory A. Rippon, MD, MS • Brandon Pence • Roger Lane, MD, MPH

10:30am EDT

Innovation Insights: An Analysis of the Evolving Landscape of Nucleic Acid-Based TherapeuticsTracy Humphries

10:50am EDT

Executive Interview: Jason Martin, Vice President, Cell Therapy Operations Global Manufacturing Science and Technology, Bristol Myers SquibbFraiser Kansteiner • Jason Martin

11:10am EDT

From Clinical to Commercialization: Best Practices for an Integrated Advanced Therapies Value ChainBengt-Simon Feth

11:30am EDT

Executive Interview: Matthew Truppo, PhD, Global Head of Research Platforms, SanofiJames Waldron • Matthew Truppo, Ph.D.

11:50am EDT

Translating mRNA-Based Medicines from Concept to ClinicLloyd Jeffs

12:10pm EDT

Networking Break

1:00pm EDT

AI in Drug Discovery Grows UpConor Hale • Andrew Hopkins • Gregory Verdine, Ph.D. • Iker Huerga • Andrew A. Radin

2:00pm EDT

Bringing Gene Therapies to Life: Navigating Scale Up, Leveraging Partnerships and Breaking Down Barriers to Make These a RealityBen Josey Ph.D. • William Swaney, M.S. • Gabriela Denning, Ph.D. • Anindya Dasgupta, Ph.D.

2:20pm EDT

Executive Interview: Ulrike Buchwald, Executive Director and Section Head for Pneumococcal Vaccines Research, Merck Research Laboratories (MRL)Kevin Dunleavy • Ulrike Buchwald

2:40pm EDT

Executive Interview: Ryan Potts, Ph.D., Executive Director, Research and Head of the Induced Proximity Platform, Amgen, Inc.Gabrielle Masson • Ryan Potts, Ph.D.

9:30am EDT

What are Cell and Gene Therapies Worth?Eric Sagonowsky • Steven D. Pearson, M.D., MSc • Tay Salimullah • Brett Sahli • Kelley Miller

10:30am EDT

Investing for Commercial Success as an Emerging CompanySachin Purwar

10:50am EDT

Executive Interview: Andrew Adams, VP-Neurodegeneration Res & Co-Director, Lilly Institute for Genetic MedicinesMax Bayer • Andrew Adams, Ph.D.

11:10am EDT

Executive Interview: Max Lataillade, Vice President, Head of Global Research Strategy, ViiV HealthcareAnnalee Armstrong • Max Lataillade

11:30am EDT

Executive Interview: Dr. Kim Branson, SVP and Global Head of Artificial Intelligence and Machine Learning, GSKAndrea Park • Dr. Kim Branson

11:50am EDT

Networking Break

1:00pm EDT

The E in ESG: How Biopharma is Tackling Carbon NeutralityFraiser Kansteiner • Jason Snape • Katrine DiBona • Lara Ramsburg • Jim Weidner • James Goudreau

2:00pm EDT

Executive Interview: Daniel J. Anderson, Ph.D., Chief Scientific Officer, Eikon TherapeuticsMax Bayer • Daniel J. Anderson, Ph.D.